Published in Gene Therapy Weekly, April 6th, 2006
During the regulatory approval process that included a comprehensive review of the clinical protocol and safety features of the vector by the CHR, U.S Food and Drug Administration (FDA) and the Recombinant DNA Advisory Committee (RAC) of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.